Taisho said to near $1.6-billion deal for Bristol-Myers's UPSA - Bloomberg
Reuters
Published Dec 17, 2018 05:16
Taisho said to near $1.6-billion deal for Bristol-Myers's UPSA - Bloomberg
(Reuters) - Japanese healthcare firm Taisho Pharmaceutical Holdings Co Ltd (T:4581) is said to be close to a $1.6 billion deal for Bristol-Myers Squibb Co's (N:BMY) French over-the-counter drugs business UPSA, Bloomberg reported on Sunday, citing sources familiar with the matter.
An agreement for the consumer-health business could be announced as soon as this week, according to the report https://bloom.bg/2QyHulF.
Bristol-Myers Squibb said in an email to Reuters that it does not comment on rumours and speculation, adding that the company is still considering options for the strategic review of UPSA that was announced in June.
A Taisho spokesman said the company could not comment on the report.
German drugmaker Stada (D:STAGn) and Italian healthcare company Angelini were among the final bidders for Bristol-Myers' UPSA unit, according to a Reuters report in November.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.